Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
November 8, 2017
MILLENDO THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 2 RESULTS OF ATR-101 IN CLASSIC CONGENITAL ADRENAL HYPERPLASIA
November 7, 2017
TAKEDA AND PORTAL INSTRUMENTS ANNOUNCE COLLABORATION TO DEVELOP NEEDLE-FREE DRUG DELIVERY DEVICE
November 6, 2017
NOUSCOM RAISES €42 MILLION SERIES B FINANCING
October 31, 2017
IMPEL NEUROPHARMA ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF INP104 FOR TREATMENT OF ACUTE MIGRAINE HEADACHE
October 26, 2017
CRINETICS PHARMACEUTICALS INITIATES PHASE 1 STUDY OF LEAD CANDIDATE CRN00808 FOR ACROMEGALY
October 24, 2017
SCPHARMACEUTICALS FILES FOR A $100 MILLION IPO
October 18, 2017
SPYRYX BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF SPX-101 FOR THE TREATMENT OF CYSTIC FIBROSIS
October 18, 2017
PEAR THERAPEUTICS RECEIVES EXPEDITED ACCESS PATHWAY DESIGNATION FROM FDA FOR RESET-O™ PRESCRIPTION DIGITAL THERAPEUTIC TO TREAT OPIOID USE DISORDER
October 18, 2017
VIVEVE RELEASES PRELIMINARY THIRD QUARTER 2017 FINANCIAL RESULTS
October 16, 2017
APREA THERAPEUTICS ANNOUNCES FIRST PATIENTS ENROLLED IN PHASE IB/II CLINICAL STUDY OF APR-246 FOR THE TREATMENT OF ESOPHAGEAL CANCER
« Previous Page
1
…
81
82
83
84
85
…
118
Next Page »